HELP Company Profile and Key Details

HELP has shown sold momentum, gaining 4.07% over the past week and 27.36% over the past quarter, though year-to-date performance is down -6.11%. Short-term trend indicators are mixed aligned (SMA20 16.3%, SMA50 7.43%, SMA200 10.61%). The stock’s 14-day RSI is 61.95 (firm momentum), while the ATR of 0.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.06% below its high and over 61.33% above its low. Average 10-day trading volume of 1.30 million shares is below the 3-month average of 1.63 million, indicating normal recent market interest.

Cybin Inc. Common Stock generated EPS of -$4.52 over the past year. Five-year average earnings growth is -232.48%. Wall Street analysts project EPS growth of 13.28% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $95.00 to $8.00. The high target offers 677.41% upside. The low target suggests -34.53% downside. The mean target is $48.83. This offers 299.59% upside. Cybin Inc. Common Stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 14, 2026, missed forecasts by 7.37%. The prior quarter beat by 15.27%. Over the last six quarters, Apple has recorded several small beats. These include 14.72% in August 13, 2025.

Cybin Inc. Common Stock (NASDAQ:HELP) closed at $12.22 USD, gaining $0.45 (3.82%) from the previous close of $11.77. The stock is currently mid-range between its 52-week high and low $3.76 and $14.35. With a market capitalization of about $757.45 million, Cybin Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 1.66 million shares, volume is running light vs its 52-week average. Headquartered in Toronto, ON, Cybin Inc. Common Stock operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Michael I. Halstead, the company employs approximately 100 people and listed since September 13, 2019. Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds.

Cybin Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.19. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Cybin Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.32%, with price expected at $13.97 by September 18, 2026, within a range of $12.85 to $15.00 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 03, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected gain of 217.76%, with price at $38.83 by September 03, 2027, within a range of $38.71 to $39.01.

Cybin Inc. Common Stock (NASDAQ:HELP) shares are flat -6.11% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cybin Inc. Common Stock trading at a premium to the broader market with a P/E of -2.19. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.83, suggesting 299.59% upside. Our AI forecast model points to short-term strength (14.32% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (217.76% over one year), with expected trading ranges indicating moderate volatility.

Cybin Inc. Common Stock trades at a P/E ratio of -2.19, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.61 suggesting the stock is closer to book value. The P/FCF stands at -4.84, also below market averages.